CYTAXIN POWDER FOR SOLUTION FOR INJECTION 0.5GVIAL

Χώρα: Σιγκαπούρη

Γλώσσα: Αγγλικά

Πηγή: HSA (Health Sciences Authority)

Δραστική ουσία:

Cefotaxime Sodium equivalent to Cefotaxime

Διαθέσιμο από:

PHARMAKOE PTE. LTD.

Φαρμακολογική κατηγορία (ATC):

J01DD01

Φαρμακοτεχνική μορφή:

INJECTION, POWDER, FOR SOLUTION

Σύνθεση:

Cefotaxime Sodium equivalent to Cefotaxime 0.5g/vial

Οδός χορήγησης:

INTRAVENOUS, INTRAMUSCULAR

Τρόπος διάθεσης:

Prescription Only

Κατασκευάζεται από:

TENAMYD PHARMACEUTICAL CORPORATION

Καθεστώς αδειοδότησης:

ACTIVE

Ημερομηνία της άδειας:

2021-11-10

Αρχείο Π.Χ.Π.

PRODUCT INFORMATION
Company logo
CYTAXIN
CEFOTAXIME POWDER FOR
SOLUTION FOR INJECTION 0.5G & 1G
COMPOSITION:
CYTAXIN
0.5G:
Each vial of dry powder contains 524mg cefotaxime sodium,
corresponding to
500mg cefotaxime.
CYTAXIN
1G:
Each vial of dry powder contains 1048mg cefotaxime sodium,
corresponding to
1000mg cefotaxime.
DESCRIPTION:
CYTAXIN
0.5G:
Off-white to pale yellow crystalline powder. After reconstitution, the
solution
should be pale yellow to light amber colour.
CYTAXIN
1G:
Off-white to pale yellow crystalline powder. After reconstitution, the
solution should
be pale yellow to light amber colour.
PROPERTIES
Cytaxin is an antibiotic of the cephalosporin group and has a
bactericidal effect. Its antibiotic
activity against Gram-negative rod-shaped bacteria is many times
stronger than that of the
traditional cephalosporin and penicillins. In most pathogens, its
minimum bactericidal
concentration is slightly higher than its minimum inhibitory
concentration.
Resistance develops slowly, as with penicillin. In vitro studies of
combinations of Cefotaxime
with aminoglycoside antibiotics reveal a synergistic or additive
effect.
The serum protein binding is 32 – 50%, depending on the method used,
After injection, high Cefotaxime concentrations clearly exceeding the
susceptibility of most
pathogens are obtained in serum, tissues, and body fluids.
Cefotaxime is excreted mainly through the kidneys in an
antibacterially active form.
INDICATIONS
Severe infections caused by cefotaxime-susceptible pathogens;
Infections
- of the respiratory tract, including nose and throat
- of the ear
- of the kidneys and urinary tract,
- of the skin and soft tissues
- of the bones and joints,
- of the genital organs including gonorrhoea,
- of the abdominal region
Sepsis, endocartitis, meningitis: for perioperative prophylaxis in
patients who are at increased risk
from infection, and for the prophylaxis of infections in patients with
reduced resistance.
Cefotaxime is generally effective against the following pathogens:
Staphylococci, aero